Chemoresistance-Motility Signature of Molecular Evolution to Chemotherapy in Non-Muscle-Invasive Bladder Cancer and Its Clinical Implications

Jeong, M.-S., Baek, S.-W., Yang, G.-E., Mun, J.-Y., Kim, J. A., Kim, T.-N., Nam, J.-K., Choi, Y.-H., Lee, J.-S., Chu, I.-S., & Leem, S.-H. (2025). Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. Cancer Letters, 610, 217339. https://doi.org/10.1016/j.canlet.2024.217339
Authors:
Mi-So Jeong
Seung-Woo Baek
Gi-Eun Yang
Jeong-Yeon Mun
Jeong‐Ah Kim
Tae Nam Kim
Jong-Kil Nam
Yung Hyun Choi
Ju‐Seog Lee
In‐Sun Chu
Sun‐Hee Leem
Affiliated Authors:
Jeong-Yeon Mun
Columbia Affiliation:
Subjects:
Urinary Bladder Neoplasms (MeSH)
Drug Resistance, Neoplasm (MeSH)
Gemcitabine (MeSH)
Deoxycytidine (MeSH)
Diagnosis and Treatment of Bladder Cancer (OpenAlex Topic)
Epigenetic Modifications and Their Functional Implications (OpenAlex Topic)
Mechanisms and Implications of Ferroptosis in Cancer (OpenAlex Topic)
Author Keywords:
alternative chemotherapy
cancer-associated fibroblast
chemoresistance-motility signature
immunotherapy
non-muscle-invasive bladder cancer
stepwise molecular evolution
elink
Publication Type:
Article
Unique ID:
10.1016/j.canlet.2024.217339
PMID:
39608442
DOI:
10.1016/j.canlet.2024.217339
Journal:
Cancer Letters
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Web of Science Record
View Scopus Record

Record Created: